This article was originally published in The Tan Sheet
Executive SummaryIncreased advertising promoting firm's Schiff Move Free joint supplement starts to pay off as product's sales rise 10% in the second quarter ended Nov. 30, CEO Bruce Wood reports in Dec. 18 earnings call. Weider revenues grew 4.7% to $60.8 mil. on a quarter-to-quarter basis, primarily due to the higher Move Free sales. "We are committed to continuing a high level of consumer marketing investment on Move Free throughout the balance of the fiscal year," Wood says...
You may also be interested in...
A BLA filing for Zynteglo in beta-thalassemia is expected in the second half of 2020 instead of the first half, but the first commercial patient in the EU will be treated in the first half of this year.
Amid the ongoing spread of the coronavirus outbreak, China turns to novel and repurposed antiviral drugs but also courts traditional medicines to ease public fear over the largely unknown threat.
With Pataday Once Daily Relief (0.2% olopatadine) and Twice Daily (0.1%), Alcon adds allergy treatment to its lineup of OTC drops indicated for dry eye and redness. “Obviously, eye allergy will become a much bigger part of the portfolio for us,” says US vision care GM Sean Clark.